Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ORGANIZATION
ORGANIZATION
- Kenporen Director Calls on Pharma Industry, MHLW to Share More Data toward FY2024 Reform
January 20, 2023
- JPMA Now Finalizing Policy Proposal 2023, Due Out “before Cherry Blossoms”
January 20, 2023
- Japan Pharma Lobbies Look Set to Shift to Okada/Ueno Leadership towards FY2024 Reform
January 17, 2023
- ALS Patient Group Petitions for Early Approval of Relyvrio in Japan
January 12, 2023
- FPMAJ Chief Poised to Push Rethink of Price Revision Rules towards FY2024 Reform
January 11, 2023
- Japan Pharma Leaders Want to Thwart “Drug Loss,” Return of Lag: New Year’s Messages
January 5, 2023
- FPMAJ Calls on Drug Makers to Lift Shipment Controls of 233 APIs/Specifications
December 28, 2022
- Generic Use Rate Hits Record 80.3% in July-September: JGA
December 28, 2022
- Hodanren Questions Special PMP Measure in Off-Year Drug Price Revision
December 27, 2022
- Product Coverage for FY2023 Price Revision “Deeply Regrettable”: FPMAJ
December 22, 2022
- Japan Hospital Federation Calls for Drug Pricing Overhaul in FY2024
December 20, 2022
- Japan Citizen’s Group Opposes NIP Inclusion of Silgard 9
December 19, 2022
- Ease API Regulations to US and European Levels to Stop Generic Woes: JEMA
December 15, 2022
- Lilly’s Simone Thomsen to Become PhRMA Japan Chair in January
December 7, 2022
- FPMAJ Poll Finds Worsening Supply Woes with 28% of Drugs Restricted or Suspended
December 7, 2022
- 88% of Japanese Have Confidence in Pharma Industry: JPMA
December 6, 2022
- Exclude Patented Drugs from Off-Year Price Revision: JPMA, PhRMA, EFPIA
November 24, 2022
- Citizen’s Group Renews Opposition to Emergency Approval of Shionogi COVID-19 Pill
November 22, 2022
- Increasing Number of Lawmakers Are Against Off-Year Price Revision: JPMA Director General
November 18, 2022
- JPMA Lauds Govt’s Proposed Extra Budget for Enhanced Startup Support
November 10, 2022
ページ
Japan’s health and finance ministers agreed late last year to go ahead with an “off-year” drug price revision in FY2027,…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…